Plethora's European Phase III premature ejaculation study meets
Pharmaceutical Business Review - Nov 7, 2008
(p<0.0001) and a six point difference between PSD502 and placebo in the index of premature ejaculation (IPE) domain for sexual satisfaction (p<0.0001),